STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1906 by analyst upside · 2026-08-13
BMRN
BioMarin Pharmaceutical Inc.
Healthcare · Market Cap $14B · P/E 189.8x
ANALYST PRICE TARGET
+28.6%
implied upside to consensus target
Current Price $70.24
Consensus Target $90.32
Bull Target $124.0
Bear Target $60.0
Analysts Covering 25
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
13
Hold
6
Sell
0
52-Week Low $49.26
52-Week High $70.98
YTD Return +18.1%
FUNDAMENTALS
Market Cap $14B
P/E Ratio (TTM) 189.8x
Forward P/E 10.6x
EPS (TTM) $0.37
PEG Ratio 0.86
Dividend Yield N/A
Revenue (TTM) $3.4B
Profit Margin 2.1%
52-WEEK RANGE
52-Week Low $49.26
52-Week High $70.98
Current Price $70.24
Bear Target $60.0
Bull Target $124.0
● Now $70.24 ● Target $90.32
TRADING DATA
Avg Volume 2.2M
YTD Return +18.1%
Analyst Count 25
Consensus Buy
Upside to Target +28.6%
Last Updated 2026-08-13

ANALYST SUMMARY

BioMarin Pharmaceutical Inc. (BMRN) is currently trading at $70.24 with a Wall Street consensus price target of $90.32, implying potential upside of 28.6% over the next 12 months. 25 analysts currently cover BMRN, with a consensus rating of Buy - 76% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $124.0, while the most cautious has a target of $60.0.

BMRN operates in the Healthcare sector with a market capitalisation of $14B. The stock is up 18.1% year-to-date and is currently trading near the upper end of its 52-week range of $49.26 – $70.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BMRN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-05-22 Building track record
B of A Securities - Reiterated
Buy → Buy 2026-05-19 Building track record
Citigroup ● Initiated
Buy 2026-05-19 Building track record
HC Wainwright & Co. - Reiterated
Neutral → Neutral 2026-05-18 31% win rate (48 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-05-07 Building track record
Bernstein - Reiterated
Outperform → Outperform 2026-05-05 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-05 Building track record
RBC Capital reit
Sector Perform → Sector Perform 2026-05-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
25/30
Consensus clarity
12/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →